![](https://ml.globenewswire.com/media/0392544b-ecff-4590-9eed-59c934e1ba4d/small/artiva-biotherapeutics-logo-jpg.jpg)
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indications Treated first patient …